NOW AVAILABLE: For the European Psoriasis Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q4, 2016.

Humira kept its status as promotions leader during Q4, producing 29% of the total promotional volume. Enbrel promoted its status as a biologic approved for PsO pediatric patients, while Humira featured its new enhanced presentation. The brands focused on patient convenience, new approvals, new clinical studies, and patient services, while biosimilars maintained comparability and cost-savings as main promotional messages. Additional insights into marketing strategies and channel utilization are available in the full Q4 report.

2016-Q4-Psoriasis

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Primary Care Markets and Specialty Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com